

Supplemental Material

Dual antiplatelet therapy using cilostazol with aspirin or clopidogrel: Subanalysis of the CSPS.com trial

Haruhiko Hoshino, MD¹; Kazunori Toyoda, MD²; Katsuhiko Omae, PhD³; Noriyuki Ishida, BSN³; Shinichiro Uchiyama, MD⁴; Kazumi Kimura, MD⁵; Nobuyuki Sakai, MD⁶; Yasushi Okada, MD⁷; Kortaro Tanaka, MD⁸; Hideki Origasa, PhD⁹; Hiroaki Naritomi, MD¹⁰; Kiyohiro Houkin, MD¹¹; Keiji Yamaguchi, MD¹²; Masanori Isobe, MD¹³; Kazuo Minematsu, MD¹⁴; Masayasu Matsumoto, MD¹⁵; Teiji Tominaga, MD¹⁶; Hidekazu Tomimoto, MD¹⁷; Yasuo Terayama, MD¹⁸; Satoshi Yasuda, MD¹⁹; Takenori Yamaguchi, MD²; on behalf of the CSPS.com Trial Investigators

Supplemental Figure

Primary efficacy outcome of ischemic stroke in the clopidogrel group, according to prespecified subgroups

